From: Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
ER-positive | ER-negative | |||||
---|---|---|---|---|---|---|
HMG-CoAR intensity | 0 | 1–3 | 0 | 1–3 | ||
n (%) | 88 (23) | 294 (77) | p value | 22 (38) | 36 (62) | p value |
Age (years) | ||||||
Median | 66 | 65 | 57 | 59 | ||
Range | 28–89 | 35–96 | 0.43 | 27–81 | 34–90 | 0.38 |
≤50 | 15 (17) | 45 (15) | 7 (32) | 8 (27) | ||
>50 | 73 (83) | 249 (85) | 0.69 | 15 (68) | 28 (73) | 0.42 |
Tumour size | ||||||
Median | 20 | 15 | 22 | 17 | ||
Range | 1 to 100 | 1 to 100 | <0.001 | 12 to 55 | 1 to 100 | 0.10 |
≥20 mm | 48 (55) | 147 (60) | 9 (41) | 19 (53) | ||
>20 mm | 40 (45) | 97 (40) | 0.03 | 13 (59) | 17 (47) | 0.38 |
NHG | ||||||
I | 11 (13) | 95 (32) | 0 | 1 (3) | ||
II | 40 (45) | 126 (43) | 5 (23) | 9 (25) | ||
III | 37 (42) | 72 (25) | <0.001 | 17 (77) | 26 (72) | 0.56 |
Node status | ||||||
Negative | 48 (59) | 167 (64) | 19 (90) | 11 (36) | ||
Positive | 33 (41) | 95 (36) | 0.47 | 2 (10) | 19 (63) | <0.001 |
Unknown | 7 | 32 | 1 | 6 | ||
Tamoxifen | ||||||
No | 41 (55) | 133 (60) | 8 (50) | 12 (44) | ||
Yes | 33 (45) | 87 (40) | 0.45 | 8 (50) | 15 (56) | 0.73 |
Unknown | 14 | 74 | 6 | 6 | ||
Chemotherapy | ||||||
No | 67 (91) | 214 (96) | 14 (88) | 23 (85) | ||
Yes | 7 (9) | 8 (4) | 0.05 | 2 (12) | 4 (15) | 0.84 |
Unknown | 14 | 72 | 6 | 6 | ||
HER2 IHC | ||||||
0 | 59 (71) | 144 (51) | 17 (81) | 12 (34) | ||
1 | 13 (16) | 85 (30) | 0 | 5 (14) | ||
2 | 6 (7) | 35 (12) | 0 | 1 (3) | ||
3 | 5 (6) | 19 (7) | 0.02 | 4 (19) | 17 (49) | 0.007 |
Unknown | 5 | 11 | 1 | 1 | ||
HER2 IHC | ||||||
0 to 2 | 78 (94) | 264 (93) | 17 (80) | 18 (51) | ||
3 | 5 (6) | 19 (7) | 0.82 | 4 (20) | 17 (49) | 0.02 |
Unknown | 5 | 11 | 1 | 1 | ||
Ki67 | ||||||
0 to 10% | 27 (32) | 116 (42) | 1 (5) | 4 (12) | ||
11 to 25% | 32 (38) | 101 (37) | 3 (15) | 7 (21) | ||
>25% | 25 (30) | 58 (21) | 0.05 | 16 (80) | 23 (68) | 0.30 |
Unknown | 4 | 19 | 2 | 1 |